Majority of the people tend to believe that any ailment or disorder is caused by an infection, bacteria or virus. But the truth is that sometimes, diseases can occur when the body is attacked by the very systems and mechanisms that are created to protect it. In this article, we will introduce you to seven rare-occurring autoimmune disorders that you might not even know, and how biotech researchers are developing treatments to cure them.
The immune system present within our body is capable of exhibiting a damaging response to both, foreign viruses and bacteria and its own tissues. If the immune system is hyperactive, it cause serious damages within the body, and the patient can end up suffering with more than one autoimmune disorders in a short span of time. There are various kinds of autoimmune diseases that trigger inflammation within the thyroid glands, triggering severe hormonal imbalances.
We all know a great deal about various common yet rare autoimmune ailments as they are a regular part of our lives, for instance, multiple sclerosis. This autoimmune disease occurs when the immune system attacks he myelin sheath of the nerve cells. Type 1 diabetes occurs when the immune system destroys the pancreatic cells and puts an end to the body’s natural insulin production. Rheumatoid arthritis tends to occur due to inflammation within the joints, and lupus occurs when the entire body is being attacked by the immune system.
There are many other rarely-occurring kinds of autoimmune disorders that tend to cause grave harm and damage to the body, and we have discussed seven such diseases and the treatments that biotech is developing to cure them.
Here’s everything you need to know:
1. Grave’s Disease
Grave’s disease is triggered when the antibodies cause the thyroid to release a significant amount of the thyroid hormone, which tends to trigger symptoms such as tremors, irregular heartbeats and redness of the skin. Doctors commonly treat these symptoms by removing the thyroid gland, and putting their patients on lifelong sessions of the hormone replacement therapy.
However, it is important to consider that synthetic thyroxine can lead to hypothyroidism, an ailment that causes the thyroid gland to be mostly inactive. This is why researchers are devoted to the development of new alternatives and safer treatments to cure the Grave’s disease.
Apitope, a British-Belgian biotech company, has developed a first-in-class treatment to cure Grave’s disease, and this year, it garnered effective results in a Phase I trial. This treatment is powered by a protein that causes the white blood cells, which attack the thyroid gland, to become inactivated.
Majority of the people believe that a dermatological ailment such as psoriasis can only cause facial discomfort and cosmetic disadvantages, but this is a prevalent misconception that needs to be altered. Psoriasis can lead to horrid flare-ups that cause severe skin damage and the pain is a lot similar to that of burn victims.
These symptoms make it impossible for the patient to normally regulate body temperature, and it also reduces their immunity against fatalistic infections. Modern science has developed various palliative care and biologics to cure psoriasis that work to block certain cells and proteins that are involved in inducing the symptoms. Recent research reveals that antibody therapies and treatments are likely to be a much more beneficial alternative, and biotech organizations are competing to launch their treatments in a volatile market.
LEO Pharma, a Danish biotech organization, is leading the market with Kyntheum, its antibody that has garnered European approval. It is followed by MorphoSys, a German biotech that has also garnered approval from the EMA for its latest release, the antibody guselkumad, which is all set to outsell other drugs. AbbVie has developed Humira, an antibody that has proven effective in treating various rarely-occurring autoimmune diseases.
Escalier Biosciences, a Dutch biotech company, collected €15M to produce needle-free treatments to cure the symptoms of psoriasis, and this treatment works by targeting a certain hormone receptor that triggers inflammation. Samsung Bioepis is also leading the market for psoriasis treatments by creating a biosimilar of Remicade (infliximab) an antibody developed by Janssen. Various other companies are currently working to produce similar treatments, including Affibody, Switch Biotech and Delenex Therapeutics.